What is Warm Autoimmune Hemolytic Anemia (wAIHA)?
Warm autoimmune hemolytic anemia (wAIHA) is a rare, life-threatening autoimmune disease in which the immune system produces erroneous immunoglobulin G (IgG) autoantibodies that attach to and destroy red blood cells, leading to severe anemia, debilitating fatigue, and significantly increased risks of morbidity and mortality.
Previously, patients with wAIHA had to rely on non-specific therapies such as corticosteroids and immunosuppressants, which suppress the entire immune system without precisely targeting the disease-driving IgG autoantibodies—resulting in limited efficacy and notable side effects.
IMAAVY: The World's First Targeted Therapy for wAIHA
On August 24, 2026, Johnson & Johnson announced that the U.S. FDA has approved IMAAVY® (nipocalimab-aahu) for the treatment of wAIHA in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. This marks the first time a therapy has been proven safe and effective specifically for wAIHA, representing a paradigm shift in the management of this disease.
IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic IgG autoantibodies while preserving B-cell function, intervening at the root cause of the disease.
Clinical Evidence: Significant Improvements in Hemoglobin and Fatigue
The approval is based on the pivotal Phase 2/3 ENERGY trial results:
- Durable hemoglobin response: Approximately three times as many patients receiving the approved dose of IMAAVY (30 mg/kg every 4 weeks) achieved durable hemoglobin response by 24 weeks compared with placebo.
- Rapid onset: A mean increase in hemoglobin of 1 g/dL was observed at Week 1; the median time to first response was 4.1 weeks (range: 1-12) in IMAAVY-treated patients versus 12.1 weeks in the placebo group.
- Fatigue improvement: At Week 24, IMAAVY was associated with a 3.5-point higher mean FACIT-Fatigue score versus placebo, indicating significantly reduced fatigue.
- Safety: The safety profile was consistent with the established profile of IMAAVY in generalized myasthenia gravis (gMG). The most common adverse reactions (≥10%) were peripheral edema, diarrhea, and fever.
What This Means for Patients
Patients with wAIHA often experience recurrent cycles of disease fluctuation—sudden drops in hemoglobin, profound exhaustion, and severely impaired quality of life. The approval of IMAAVY provides this long-overlooked community with the first treatment specifically targeting the underlying cause of the disease, potentially redefining the standard of care for wAIHA.
Johnson & Johnson noted that IMAAVY was previously approved in April 2025 for the treatment of generalized myasthenia gravis (gMG) in AChR or MuSK antibody-positive patients. This wAIHA indication represents another significant milestone in the drug's development for autoantibody-driven diseases.
If you or a family member are monitoring autoimmune disease management, consider using the Xiaoshu Health App—it syncs with Apple Health to track blood oxygen, heart rate, activity levels, and other metrics, helping you continuously monitor your health status and providing more complete data for discussions with your healthcare provider.